United Therapeutics (UTHR) Set to Announce Quarterly Earnings on Wednesday

United Therapeutics (NASDAQ:UTHR) will post its quarterly earnings results before the market opens on Wednesday, October 30th. Analysts expect United Therapeutics to post earnings of $6.16 per share for the quarter.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 EPS for the quarter, missing the consensus estimate of $6.33 by ($0.48). The business had revenue of $714.90 million during the quarter, compared to analyst estimates of $691.87 million. United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The firm’s revenue was up 19.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $5.24 earnings per share. On average, analysts expect United Therapeutics to post $25 EPS for the current fiscal year and $28 EPS for the next fiscal year.

United Therapeutics Stock Down 4.8 %

Shares of UTHR opened at $352.58 on Thursday. The company has a market capitalization of $15.64 billion, a P/E ratio of 16.67, a PEG ratio of 1.35 and a beta of 0.57. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.35 and a quick ratio of 4.18. United Therapeutics has a one year low of $208.62 and a one year high of $377.03. The business’s 50 day simple moving average is $352.90 and its 200-day simple moving average is $311.21.

Insider Transactions at United Therapeutics

In other news, Director Raymond Dwek sold 5,000 shares of the firm’s stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $325.35, for a total transaction of $1,626,750.00. Following the sale, the director now owns 1,750 shares of the company’s stock, valued at $569,362.50. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, Director Raymond Dwek sold 5,000 shares of the firm’s stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $325.35, for a total transaction of $1,626,750.00. Following the sale, the director now owns 1,750 shares of the company’s stock, valued at $569,362.50. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO James Edgemond sold 7,782 shares of United Therapeutics stock in a transaction that occurred on Monday, October 21st. The shares were sold at an average price of $366.99, for a total value of $2,855,916.18. Following the completion of the sale, the chief financial officer now directly owns 6,426 shares in the company, valued at approximately $2,358,277.74. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 106,412 shares of company stock valued at $36,470,922 over the last 90 days. 12.50% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research analysts have recently commented on UTHR shares. LADENBURG THALM/SH SH downgraded United Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 1st. UBS Group boosted their target price on United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a report on Monday, July 8th. Wells Fargo & Company boosted their target price on United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a report on Tuesday, August 20th. TD Cowen upped their price objective on United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $400.00 price objective on shares of United Therapeutics in a report on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, three have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $361.33.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.